These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 20375795)
41. [Clinical and pathological features of borderline ovarian tumors]. Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693 [TBL] [Abstract][Full Text] [Related]
42. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP; J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437 [TBL] [Abstract][Full Text] [Related]
43. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO. Sinukumar S; Rajan F; Mehta S; Damodaran D; Zaveri S; Kammar P; Bhatt A Eur J Surg Oncol; 2021 Jan; 47(1):75-81. PubMed ID: 30857879 [TBL] [Abstract][Full Text] [Related]
44. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA Oncology; 2013; 84(3):158-65. PubMed ID: 23296063 [TBL] [Abstract][Full Text] [Related]
45. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival? Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832 [TBL] [Abstract][Full Text] [Related]
46. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J; World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831 [TBL] [Abstract][Full Text] [Related]
47. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437 [TBL] [Abstract][Full Text] [Related]
48. Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary. Uzan C; Kane A; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P Oncologist; 2011; 16(2):189-96. PubMed ID: 21273510 [TBL] [Abstract][Full Text] [Related]
49. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453 [TBL] [Abstract][Full Text] [Related]
50. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Shih KK; Zhou QC; Aghajanian C; Huh J; Soslow RA; Morgan JC; Iasonos A; Chi DS; Barakat RR; Abu-Rustum NR Gynecol Oncol; 2010 Nov; 119(2):270-3. PubMed ID: 20719369 [TBL] [Abstract][Full Text] [Related]
51. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors. Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897 [TBL] [Abstract][Full Text] [Related]
52. Which Surgical Attitude to Choose in the Context of Non-Resectability of Ovarian Carcinomatosis: Beyond Gross Residual Disease Considerations. Vidal F; Al Thani H; Haddad P; Luyckx M; Stoeckle E; Morice P; Leblanc E; Lecuru F; Daraï E; Classe JM; Pomel C; Mahfoud Z; Ferron G; Querleu D; Rafii A Ann Surg Oncol; 2016 Feb; 23(2):434-42. PubMed ID: 26542592 [TBL] [Abstract][Full Text] [Related]
53. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193 [TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614 [TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273 [TBL] [Abstract][Full Text] [Related]
59. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. Kristensen GS; Schledermann D; Mogensen O; Jochumsen KM Int J Gynecol Cancer; 2014 Jun; 24(5):874-9. PubMed ID: 24844221 [TBL] [Abstract][Full Text] [Related]
60. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer? Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]